Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma (Nasdaq: SILO) engaged drug-device partner Resyca to run a robustness study on the microchip-based Soft-Mist nasal spray delivering SPC-15, its lead intranasal prophylactic PTSD treatment.
The 30-day study will test device performance and SPC-15 formulation stability and is expected to support a planned FDA Type C meeting and IND/Phase 1 strategy under a previously aligned 505(b)(2) pathway.
Silo Pharma (Nasdaq:SILO) reported positive stability data for its investigational PTSD prophylactic treatment SPC-15, a soft-mist intranasal formulation. Real-time data over nine months and six-month accelerated testing showed physical, chemical and microbiological stability within predefined specifications, supporting IND-enabling CMC requirements and advancement toward a first-in-human Phase 1 clinical trial.
Silo Pharma (Nasdaq: SILO) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) as of June 17, 2026. The stock will continue trading on the Nasdaq Capital Market, and the compliance matter is considered closed.
The company also highlighted confidence in advancing its lead PTSD candidate SPC-15 toward first-in-human trials and progressing its QwikAgents AI agents platform.
Silo Pharma (Nasdaq: SILO) filed a provisional USPTO patent titled “Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine.” The company will evaluate ibogaine and related compounds for TBI and associated neuropsychiatric conditions, citing reported structural brain changes and symptom reductions after single treatments. The release notes a projected $6.0 billion global TBI therapeutics market by 2032 and references recent federal actions to accelerate psychedelic drug development.
Silo Pharma (NASDAQ: SILO) welcomed coordinated U.S. federal actions on April 29, 2026 that accelerate psychedelic therapeutic research and regulatory clarity for PTSD and related disorders. Key developments include ARPA-H EVIDENT initial awardees (including Johns Hopkins), FDA issuance of three Commissioner’s National Priority Vouchers, an IND clearance to DemeRx NB, and a promised final guidance on psychedelic drug development to be published imminently.
Silo frames these moves as validating data-driven approaches to complex neurological and psychiatric conditions and says the federal actions could lay groundwork for new PTSD therapies.
Silo Pharma (Nasdaq: SILO) acquired assets of Qwikagents.ai and launched a dedicated AI subsidiary to expand into the AI agent market. The firm cites market projections of $47–$53 billion by 2030 and 43–50% annual growth. Silo also plans to submit an IND for SPC-15 to the FDA and advance its PTSD program into Phase 1 after approval.
The move creates a second business line—AI infrastructure—while retaining focus on clinical development.
Silo Pharma (NASDAQ: SILO) highlighted its lead intranasal PTSD candidate, SPC-15, and said it is positioned to benefit from renewed federal focus on psychedelic-based therapies following an April 18, 2026 executive order directing agencies to accelerate research.
SPC-15 is a 5-HT4 receptor agonist delivered intranasally via a nose-to-brain device, advanced under a 505(b)(2) regulatory pathway, backed by Columbia University-licensed IP, and preparing for IND engagement with the FDA.
Silo Pharma (Nasdaq: SILO) announced the European Patent Office issued a Rule 71(3) communication indicating intent to grant a patent (European Application No. 20786878.7) covering prophylactic use of 5-HT4 receptor agonists to prevent stress-induced fear and depressive-like behavior.
The allowance expands Silo's licensed IP from Columbia University, may protect major European markets once granted, and the company is evaluating Unitary Patent and national validations to maximize coverage.
Silo Pharma (Nasdaq: SILO) announced a board-authorized share repurchase program on February 23, 2026 to acquire up to $1,000,000 of its common stock. The program permits purchases on the open market or in privately negotiated transactions, subject to SEC rules and blackout periods.
The company reported 13,318,273 shares outstanding as of November 13, 2025. The program does not obligate the company to buy any specific number of shares and may be suspended or discontinued at the company's discretion.
Silo Pharma (Nasdaq: SILO) received a Notice of Allowance from the Japan Patent Office for a patent application covering SPC-15, its novel intranasal therapeutic targeting PTSD.
The allowed application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” covers composition and method claims and expands Silo’s international intellectual property estate in a key pharmaceutical jurisdiction.